TABLE 1.
Anti-HTLV-1 and cytotoxic activities of CBAs
| CBA | RNAC100a (μM) | pCC50b (μM) (PBMCs) | maCC50c (μM) (MOLT-3) |
|---|---|---|---|
| PRM-A | 12 | >120 | >120 |
| UDA | 1.1 | >11 | >11 |
| HHA | 0.2 | >2 | 1.8 (±0.1) |
Anti-HTLV-1 activity evaluated as the compound concentration at which no detectable tax/rex mRNA product was observed by RT-PCR at 4 weeks postinfection in cultures of PBMCs exposed to HTLV-1 by cocultivation with irrMT-2 cells and subsequently treated with the compounds under different experimental conditions.
Cytotoxic activity evaluated as the compound concentration required to cause proliferation inhibition by 50% in 1-week PBMC cultures. PBMCs from three donors were pretreated overnight with four different concentrations of the compounds, after which irrMT-2 cells were added as an allostimulus.
Cytotoxic activity evaluated as the compound concentration able to cause reduction in formazan product formation (MTS assay) by 50% in exponentially growing MOLT-3 cell cultures treated with four different concentrations of the compounds for 24 h. The data represent results derived from three different experiments.